Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 2
2005 4
2006 5
2007 5
2008 7
2009 4
2010 5
2011 2
2012 3
2013 7
2014 5
2015 10
2016 10
2017 7
2018 8
2019 5
2020 6
2021 11
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL Study Collaborators. Nyang'wa BT, et al. Among authors: moore daj. N Engl J Med. 2022 Dec 22;387(25):2331-2343. doi: 10.1056/NEJMoa2117166. N Engl J Med. 2022. PMID: 36546625 Clinical Trial.
Multidrug resistant tuberculosis.
Millard J, Ugarte-Gil C, Moore DA. Millard J, et al. Among authors: moore da. BMJ. 2015 Feb 26;350:h882. doi: 10.1136/bmj.h882. BMJ. 2015. PMID: 25721508 Review. No abstract available.
Latent Tuberculosis Infection Care.
Gaskell KM, Pillay TD, Brown J, Belton M, Mepham SO, Moore DAJ, Lipman M. Gaskell KM, et al. Among authors: moore daj. Clin Infect Dis. 2022 Nov 14;75(10):1864. doi: 10.1093/cid/ciac582. Clin Infect Dis. 2022. PMID: 35869842 No abstract available.
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT. Berry C, et al. Among authors: moore daj. Trials. 2022 Jun 13;23(1):484. doi: 10.1186/s13063-022-06331-8. Trials. 2022. PMID: 35698158 Free PMC article.
Genomic signatures of pre-resistance in Mycobacterium tuberculosis.
Torres Ortiz A, Coronel J, Vidal JR, Bonilla C, Moore DAJ, Gilman RH, Balloux F, Kon OM, Didelot X, Grandjean L. Torres Ortiz A, et al. Among authors: moore daj. Nat Commun. 2021 Dec 15;12(1):7312. doi: 10.1038/s41467-021-27616-7. Nat Commun. 2021. PMID: 34911948 Free PMC article.
The transmission of Mycobacterium tuberculosis in high burden settings.
Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, White RG, Cohen T, Cobelens FG, Wood R, Moore DA, Abubakar I. Yates TA, et al. Among authors: moore da. Lancet Infect Dis. 2016 Feb;16(2):227-38. doi: 10.1016/S1473-3099(15)00499-5. Epub 2016 Jan 26. Lancet Infect Dis. 2016. PMID: 26867464 Free article. Review.
Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis.
Cattamanchi A, Reza TF, Nalugwa T, Adams K, Nantale M, Oyuku D, Nabwire S, Babirye D, Turyahabwe S, Tucker A, Sohn H, Ferguson O, Thompson R, Shete PB, Handley MA, Ackerman S, Joloba M, Moore DAJ, Davis JL, Dowdy DW, Fielding K, Katamba A. Cattamanchi A, et al. Among authors: moore daj. N Engl J Med. 2021 Dec 23;385(26):2441-2450. doi: 10.1056/NEJMoa2105470. N Engl J Med. 2021. PMID: 34936740 Free PMC article. Clinical Trial.
114 results